Skip to main content
Premium Trial:

Request an Annual Quote

NanoString Technologies Prices $103.5M Common Stock Offering

NEW YORK (GenomeWeb) – NanoString Technologies said today that it has priced its previously announced offering of 4.5 million shares of common stock at $23 per share. Total gross proceeds from the offering would be $103.5 million.

The company itself will offer and sell 2.5 million shares, while one of its stockholders, Clarus Lifesciences, will offer and sell the other 2 million shares. NanoString also said it will grant the underwriters a 30-day option to purchase up to 675,000 additional shares. If the underwriters exercise their full over-allotment, that would raise the gross proceeds from the offering to approximately $119.0 million.

JP Morgan, UBS Investment Bank, and Cowen are acting as joint book-running managers for the offering. Baird is acting as lead manager. The offering is expected to close on or about March 22.

NanoString said it intends to use the net proceeds of the offering for working capital and general corporate purposes. It noted that it will not receive any proceeds from the sale of stock by Clarus Lifesciences.

The company reported earlier this month that its total revenues for the fourth quarter of 2018 were down about 15 percent year over year, while its product and services revenue grew 12 percent. NanoString ended 2018 with $24.4 million in cash and cash equivalents, and $69.6 million in short-term investments.

NanoString's shares fell more than 2 percent to $23.70 in Wednesday morning trading on the Nasdaq.

The Scan

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.

Study Looks at Parent Uncertainties After Children's Severe Combined Immunodeficiency Diagnoses

A qualitative study in EJHG looks at personal, practical, scientific, and existential uncertainties in parents as their children go through SCID diagnoses, treatment, and post-treatment stages.

Antimicrobial Resistance Study Highlights Key Protein Domains

By screening diverse versions of an outer membrane porin protein in Vibrio cholerae, researchers in PLOS Genetics flagged protein domain regions influencing antimicrobial resistance.

Latent HIV Found in White Blood Cells of Individuals on Long-Term Treatments

Researchers in Nature Microbiology find HIV genetic material in monocyte white blood cells and in macrophages that differentiated from them in individuals on HIV-suppressive treatment.